Kirk A. Frey

Kirk A. Frey

Auto-generated profile, based on publicly available information

Kirk A. Frey

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The University of Michigan Health System, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
NBNicolaas I Bohnen
Nicolaas I Bohnen
RARoger L Albm
Roger L Albm
RKRobert A Koeppe
Robert A Koeppe
KWKristine A Wernette
Kristine A Wernette
MKMichael R Kilbourn
Michael R Kilbourn
KFKirk A Frey
Kirk A Frey
The type-2 vesicular monoamine transporter (VMAT2) might serve as an objective biomarker of Parkinson disease (PD) severity. Thirty-one subjects with early-stage PD and 75 normal subjects underwent continuous intravenous infusion of (+)-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography (PET) imaging to estimate the striatal VMAT2 binding site density with equilibrium tracer modeling. Parkinson disease patients were evaluated clinically in the practically defined ‘off’ state with the Unified Parkinson Disease Rating Scale (UPDRS), the Hoehn and Yahr Scale (HY), and the Schwab and England Activities of Daily Living Scale (SE). In normal subjects there was age-related decline in striatal DTBZ binding, approximating 0.5% per year. In PD subjects, specific DTBZ binding was reduced in the caudate nucleus (CD; −44%), anterior putamen (−68%), and posterior putamen (PP; −77%). The PP-to-CD ratio of binding was reduced significantly in PD subjects. Dihydrotetrabenazine binding was also reduced by approximately 50% in the PD substantia nigra. Striatal binding reductions correlated significantly with PD duration and SE scores, but not with HY stage or with UPDRS motor subscale (UPDRSIII) scores. Striatal and midbrain DTBZ binding was asymmetric in PD subjects, with greatest reductions contralateral to the most clinically affected limbs. There was significant correlation between asymmetry of DTBZ binding and clinical asymmetry measured with the UPDRSIII. In HY stage 1 and 1.5 subjects ( n = 16), PP DTBZ binding contralateral to the clinically unaffected body side was reduced by 73%, indicating substantial preclinical nigrostriatal pathology in PD. We conclude that (+)-[11C]DTBZ-PET imaging displays many properties necessary of a PD biomarker.

27 June 2001 in Synapse
Verified
Journal Article
Closed access
PDF file
MSMasahiko Suzuki
Masahiko Suzuki
TDTimothy J. Desmond
Timothy J. Desmond
RARoger L. Albin
Roger L. Albin
KFKirk A. Frey
Kirk A. Frey

21 February 2007 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
NBNicolaas I. Bohnen
Nicolaas I. Bohnen
KFKirk A. Frey
Kirk A. Frey

9 May 2011 in Brain
Verified
Journal Article
Closed access
JBJ. F. Burke
J. F. Burke
RAR. L. Albin
R. L. Albin
RKR. A. Koeppe
R. A. Koeppe
BGB. Giordani
B. Giordani
MKM. R. Kilbourn
M. R. Kilbourn
KFK. A. Frey
K. A. Frey
We assessed the relationship between consensus clinical diagnostic classification and neurochemical positron emission tomography imaging of striatal vesicular monoamine transporters and cerebrocortical deposition of aβ-amyloid in mild dementia. Seventy-five subjects with mild dementia (Mini-Mental State Examination score≥18) underwent a conventional clinical evaluation followed by 11C-dihydrotetrabenazine positron emission tomography imaging of striatal vesicular monoamine transporters and 11C-Pittsburgh compound-B positron emission tomography imaging of cerebrocortical aβ-amyloid deposition. Clinical classifications were assigned by consensus of an experienced clinician panel. Neuroimaging classifications were assigned as Alzheimer's disease, frontotemporal dementia or dementia with Lewy bodies on the basis of the combined 11C-dihydrotetrabenazine and 11C-Pittsburgh compound-B results. Thirty-six subjects were classified clinically as having Alzheimer's disease, 25 as having frontotemporal dementia and 14 as having dementia with Lewy bodies. Forty-seven subjects were classified by positron emission tomography neuroimaging as having Alzheimer's disease, 15 as having dementia with Lewy bodies and 13 as having frontotemporal dementia. There was only moderate agreement between clinical consensus and neuroimaging classifications across all dementia subtypes, with discordant classifications in ∼35% of subjects (Cohen's κ=0.39). Discordant classifications were least frequent in clinical consensus Alzheimer's disease (17%), followed by dementia with Lewy bodies (29%) and were most common in frontotemporal dementia (64%). Accurate clinical classification of mild neurodegenerative dementia is challenging. Though additional post-mortem correlations are required, positron emission tomography imaging likely distinguishes subgroups corresponding to neurochemically defined pathologies. Use of these positron emission tomography imaging methods may augment clinical classifications and allow selection of more uniform subject groups in disease-modifying therapeutic trials and other prospective research involving subjects in the early stages of dementia.

1 August 2006 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
KFKirk A. Frey
Kirk A. Frey
RARoger L. Albin
Roger L. Albin
Traditional neuropathologic methods have provided only limited insight into the central nervous system abnormalities underlying Tourette syndrome. In the past 20 years, investigators have turned increasingly to in vivo neuroimaging approaches to localize, quantify, and characterize neuroanatomic, functional, and neurochemical distinctions in living subjects with Tourette syndrome. Research methods have included aggregate measures of cerebral energy metabolism, assessments of cerebral structure and size, and highly specific assessments of neurochemical markers of select neurons and synapses. Although the available data have important limitations, an encouraging convergence of findings implicates abnormal function in the Tourette syndrome striatum and in associated limbic and frontal cortical systems. (J Child Neurol 2006;21:672—677; DOI 10.2310/7010.2006.00162).

14 August 2017 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
NBNicolaas I. Bohnen
Nicolaas I. Bohnen
MMMartijn Muller
Martijn Muller
KFKirk A. Frey
Kirk A. Frey